BRAF inhibitors (BRAFi), like vemurafenib, suppress Nrf2 expression in BRAF mutant melanoma cells, although the effect is not significant, suggesting that other oncogenes also trigger the Nrf2 signaling pathway [20]. Here, NFE2L2 is linked to melanoma.